Display options
Cite
Rana Z, Diermeier S, Walsh FP, et al. Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel). 2021;14(10)doi: 10.3390/ph14101020.
Rana, Z., Diermeier, S., Walsh, F. P., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel, Switzerland), 14(10), . https://doi.org/10.3390/ph14101020
Rana, Zohaib, et al. "Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer." Pharmaceuticals (Basel, Switzerland) vol. 14,10 (2021). doi: https://doi.org/10.3390/ph14101020
Rana Z, Diermeier S, Walsh FP, Hanif M, Hartinger CG, Rosengren RJ. Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel). 2021 Oct 04;14(10). doi: 10.3390/ph14101020. PMID: 34681244; PMCID: PMC8540814.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2021 Oct 04;14(10). doi: 10.3390/ph14101020.

Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Pharmaceuticals (Basel, Switzerland)

Zohaib Rana, Sarah Diermeier, Fearghal P Walsh, Muhammad Hanif, Christian G Hartinger, Rhonda J Rosengren

Affiliations

  1. Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
  2. Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand.
  3. School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.

PMID: 34681244 PMCID: PMC8540814 DOI: 10.3390/ph14101020

Abstract

Metastatic castration-resistant prostate cancer (CRPC) has a five-year survival rate of 28%. As histone deacetylases (HDACs) are overexpressed in CRPC, the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) was trialled in CRPC patients but found to be toxic and inefficacious. Previously, we showed that novel HDAC inhibitors (Jazz90

Keywords: HDAC inhibitors; anti-angiogenesis; drug safety; metallodrugs; prostate cancer

References

  1. Tumour Biol. 2015 May;36(5):3325-36 - PubMed
  2. Prostate. 2015 Nov;75(15):1682-93 - PubMed
  3. Cell Signal. 2006 Dec;18(12):2262-71 - PubMed
  4. Urol Clin North Am. 2017 Nov;44(4):611-621 - PubMed
  5. J Biomed Sci. 2016 Nov 18;23(1):81 - PubMed
  6. Biomed Res Int. 2018 Sep 12;2018:1462802 - PubMed
  7. J Biomol Screen. 2010 Aug;15(7):820-9 - PubMed
  8. Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767 - PubMed
  9. Hepatology. 2013 Dec;58(6):2089-98 - PubMed
  10. J Immunol. 2010 Sep 15;185(6):3489-97 - PubMed
  11. Angew Chem Int Ed Engl. 2020 Aug 17;59(34):14609-14614 - PubMed
  12. Blood. 2013 Feb 21;121(8):1335-44 - PubMed
  13. World J Oncol. 2019 Apr;10(2):63-89 - PubMed
  14. Anticancer Res. 2015 Jan;35(1):229-37 - PubMed
  15. Molecules. 2017 Feb 13;22(2): - PubMed
  16. Biochem Pharmacol. 1996 Jul 12;52(1):65-71 - PubMed
  17. Clin Cancer Res. 2006 Aug 1;12(15):4628-35 - PubMed
  18. Expert Opin Drug Discov. 2014 Sep;9(9):995-1003 - PubMed
  19. Oncol Lett. 2018 May;15(5):6063-6076 - PubMed
  20. EMBO J. 2011 Aug 16;30(20):4142-56 - PubMed
  21. Oncologist. 2007 Oct;12(10):1247-52 - PubMed
  22. Int J Mol Sci. 2019 May 31;20(11): - PubMed
  23. J Hematol Oncol. 2011 Apr 23;4:18 - PubMed
  24. Invest New Drugs. 2015 Aug;33(4):969-76 - PubMed
  25. Pharmaceuticals (Basel). 2021 Jan 29;14(2): - PubMed
  26. Eur J Cancer. 2009 Sep;45(13):2402-11 - PubMed
  27. Biochem Pharmacol. 2021 Jan;183:114345 - PubMed
  28. Ther Adv Urol. 2015 Dec;7(6):388-95 - PubMed
  29. Cancer Chemother Pharmacol. 2013 Sep;72(3):537-44 - PubMed
  30. J Dermatol. 2012 Oct;39(10):823-8 - PubMed
  31. Cancers (Basel). 2019 Oct 22;11(10): - PubMed
  32. Int J Mol Sci. 2018 Apr 23;19(4): - PubMed
  33. Surgery. 2011 Sep;150(3):429-35 - PubMed
  34. ACS Chem Biol. 2019 Feb 15;14(2):142-163 - PubMed
  35. Chemistry. 2013 Jul 29;19(31):10160-9 - PubMed
  36. Blood. 2011 Jan 27;117(4):1425-35 - PubMed
  37. Transl Androl Urol. 2013 Jun;2(2):99-105 - PubMed
  38. Drug Des Devel Ther. 2017 Mar 03;11:599-616 - PubMed
  39. Biomedicines. 2020 Jan 30;8(2): - PubMed
  40. Cancer. 2009 Dec 1;115(23):5541-9 - PubMed
  41. Cancer Res. 2001 Mar 15;61(6):2736-43 - PubMed
  42. Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17535-17542 - PubMed
  43. Int J Toxicol. 2010 Jan-Feb;29(1):3-19 - PubMed
  44. PLoS One. 2010 May 03;5(5):e10431 - PubMed
  45. J Cancer Res Clin Oncol. 2019 Mar;145(3):551-559 - PubMed
  46. Cancer Med. 2015 Aug;4(8):1178-85 - PubMed
  47. Biomed Pharmacother. 2019 May;113:108731 - PubMed
  48. Blood. 2009 May 28;113(22):5669-79 - PubMed
  49. J Pharmacol Exp Ther. 2020 Jul;374(1):134-140 - PubMed
  50. Oncogene. 2002 Jan 17;21(3):427-36 - PubMed
  51. Ann Oncol. 2010 Jan;21(1):109-13 - PubMed
  52. Chem Sci. 2018 Jan 22;9(9):2443-2451 - PubMed
  53. Exp Dermatol. 2017 Feb;26(2):194-201 - PubMed
  54. Horm Cancer. 2020 Aug;11(3-4):182-190 - PubMed
  55. Cancer Res. 2000 Sep 15;60(18):5165-70 - PubMed
  56. Cancer Cell. 2017 Oct 9;32(4):474-489.e6 - PubMed
  57. Angiogenesis. 2012 Dec;15(4):543-54 - PubMed
  58. Int J Oncol. 2009 Dec;35(6):1417-22 - PubMed

Publication Types

Grant support